Cantargia Ab logo
VerifiedBiotechnology Research· Founded 2010

Cantargia Ab

Cantargia develops antibody based therapies against the target IL1RAP. The two clinical programs are nadunolimab in phase II development for treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases.

7-day free trial · no credit card

HeadquartersLund, SwedenEmployees31(11 to 50)Founded year2010Websitecantargia.comLinkedIn profileLinkedIn

Verified contacts

23

available on Kipplo

LinkedIn employees

31

11 to 50 range

Open roles

no listings

Distinct roles

20

indexed titles

Tech stack

0

tools in use

Monthly traffic

77

organic / mo

Sign up free to see all 23 verified contacts at Cantargia Ab

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Decision-makers and verified team members

23 contacts with verified email or phone · masked until revealed.

Sign up free →

Top roles at Cantargia Ab

20 distinct titles indexed · top 10 shown.

  • 2project director
  • 2senior scientist
  • 1()
  • 1, -
  • 1-,
  • 1chief financial officer
  • 1chief medical officer
  • 1chief scientific officer
  • 1clinical project manager - bioanalysis
  • 1director clinical development
  • +10more titles

Sign up to unlock all 23 contacts at Cantargia Ab

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Sign up to reveal 23 verified contacts at Cantargia Ab

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.

Cantargia Ab | Kipplo Discover